{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:00Z","timestamp":1787027340473,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optic pathway gliomas (OPGs) are rare neoplasms in children with an unpredictable clinical course. Approximately 15% of OPGs occur in patients affected by neurofibromatosis type 1 (NF1): the clinical course of these cases is more indolently than sporadic ones, and NF1 patients less frequently require treatment including surgery. Instead, over 90% of sporadic OPGs require one or more therapeutic approaches. The management of OPG is controversial. They are also characterized by a high risk of morbidity including hypothalamic damage, endocrine deficits, visual deficit and\/or neurological impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In this paper, we evaluated visual and endocrinological outcomes of a population of OPG followed at our center from 2013 to 2021, with a particular emphasis on the role of surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six patients were included in this study (mean age of 40.7 months). Tumor location on imaging was described by the Dodge classification. Five cases had NF 1. Thirteen cases received biopsy and 13 were partially resected. Histopathology revealed 19 cases of pilocytic astrocytomas, 2 pilomyxoid astrocytoma and 5 ganglioglioma. All the patients required a post-surgical adjuvant treatment according to current indications for low-grade gliomas. Molecular studies (BRAF status and mTOR\/pmTOR pathway) have been performed in 24\/26 patients, following for the use of target therapy in 11 of these patients. In our study we found that patients underwent biopsy have a better visual and endocrinological outcomes rather than patients with a tumor debulking. The five-year overall survival rate is 98% with a mean follow-up of 60 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Many children with OPGs survive with a residual tumor. They suffer from chronic diseases such as endocrine dysfunction, visual disturbance, motor deficits and poor quality of life. All patients need comprehensive diagnostic work-up including neuroimaging, clinical evaluations and neuropathology approach; at the same time, they need therapeutic decisions and concepts for the choice of timing and type of neurosurgical intervention, chemotherapy and target therapy as well as surveillance and rehabilitation to maximize survival and overall functional outcomes. Our study showed that minimal invasive surgery with the purpose of molecular characterization of the tumor is desirable to reduce morbidity correlate to surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fsurg.2022.890875","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T02:39:47Z","timestamp":1655347187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Rethinking the Management of Optic Pathway Gliomas: A Single Center Experience"],"prefix":"10.3389","volume":"9","author":[{"given":"Giada","family":"Del Baldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cacchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito Andrea","family":"Dell\u2019Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Stefania","family":"Colafati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marrazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Barresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Deodati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Capece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mastronuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2217\/cns.12.47","article-title":"Optic pathway gliomas: a review","volume":"2","author":"Fried","year":"2013","journal-title":"CNS Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"i98","DOI":"10.1093\/noajnl\/vdz054","article-title":"NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation","volume":"2","author":"Lob\u00f3n-Iglesias","year":"2020","journal-title":"Neuro-Oncol Adv"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.spen.2017.04.006","article-title":"Optic pathway gliomas","volume":"15","author":"Beres","year":"2016","journal-title":"J Pediatr Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ejpn.2015.12.002","article-title":"Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort","volume":"20","author":"Blanchard","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ajmg.a.20650","article-title":"Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1","author":"Blazo","year":"2004","journal-title":"Am J Med Genet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jpeds.2015.07.001","article-title":"The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1","volume":"167","author":"Prada","year":"2015","journal-title":"J Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1136\/bjophthalmol-2017-311305","article-title":"Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort","volume":"102","author":"Falzon","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-3-319-09066-5_7","article-title":"Optic pathway gliomas","volume":"42","author":"Shofty","year":"2015","journal-title":"Adv Tech Stand Neurosurg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1002\/cncr.29649","article-title":"Long-term visual outcome after chemotherapy for optic pathway glioma in children: site and age are strongly predictive","volume":"121","author":"Dodgshun","year":"2015","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.ejca.2006.02.022","article-title":"Prognostic factors for progression of childhood optic pathway glioma: a systematic review","volume":"42","author":"Opocher","year":"2006","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pediatrneurol.2017.06.019","article-title":"Clinical presentation and outcome of patients with optic pathway glioma","volume":"75","author":"Robert-Boire","year":"2017","journal-title":"Pediatr Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3171\/2017.6.PEDS17107","article-title":"Isolated optic nerve gliomas: a multicenter historical cohort study","volume":"20","author":"Shofty","year":"2017","journal-title":"Br J Neurosurg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1212\/WNL.0000000000002771","article-title":"Quantitative MRI criteria for optic pathway enlargement in neurofibromatosis type 1","volume":"86","author":"Avery","year":"2016","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/archopht.119.4.516","article-title":"Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging","volume":"119","author":"Parsa","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/neuonc\/noaa036","article-title":"Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference","volume":"22","author":"Packer","year":"2020","journal-title":"Neuro-Oncology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/archneurpsyc.1958.02340060003001","article-title":"Gliomas of the optic nerves","volume":"79","author":"Dodge","year":"1958","journal-title":"Arch NeurPsych"},{"key":"B18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1259\/bjr\/65246351","article-title":"Radiological classification of optic pathway gliomas: experience of a modified functional classification system","volume":"81","author":"Taylor","year":"2008","journal-title":"BJR"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/01.icu.0000193070.32369.37","article-title":"Optic-nerve gliomas, chiasmal gliomas and neurofibromatosis type 1","volume":"17","author":"Sylvester","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-011-0783-2","article-title":"Characterization and outcomes of optic nerve gliomas: a population-based analysis","volume":"107","author":"Mishra","year":"2012","journal-title":"J Neurooncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/ana.21107","article-title":"Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations","volume":"61","author":"Listernick","year":"2007","journal-title":"Ann Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2013.8.PEDS12546","article-title":"The role of surgery in optic pathway\/hypothalamic gliomas in children: clinical article","volume":"13","author":"Goodden","year":"2014","journal-title":"PED"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00381-021-05060-8","article-title":"Neurosurgical experience of managing optic pathway gliomas","volume":"37","author":"Hill","year":"2021","journal-title":"Childs Nerv Syst"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the children\u2019s oncology group","volume":"30","author":"Ater","year":"2012","journal-title":"JCO"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"JCO"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1004","DOI":"10.1111\/aos.13803","article-title":"Correlation of peripapillary retinal nerve fibre layer thickness with visual acuity in paediatric patients affected by optic pathway glioma","volume":"96","author":"Parrozzani","year":"2018","journal-title":"Acta Ophthalmologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ghir.2012.04.005","article-title":"Serum insulin-like growth factor-I (IGF-I) reference ranges for chemiluminescence assay in childhood and adolescence. Data from a population of in- and out-patients","volume":"22","author":"Bedogni","year":"2012","journal-title":"Growth Horm IGF Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ghir.2012.04.005","article-title":"Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3)","volume":"42","author":"Elmlinger","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/pbc.20655","article-title":"Optic pathway gliomas","volume":"46","author":"Jahraus","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/MPH.0b013e318162bd6a","article-title":"Treatment of optic pathway hypothalamic gliomas in childhood: experience with 18 consecutive cases","volume":"30","author":"Jaing","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1586\/14737140.7.11.1591","article-title":"Management of optic\u2013hypothalamic gliomas in children: still a challenging problem","volume":"7","author":"Massimi","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"dgaa138","DOI":"10.1210\/clinem\/dgaa138","article-title":"Pretreatment endocrine disorders due to optic pathway gliomas in pediatric neurofibromatosis type 1: multicenter study","volume":"105","author":"Santoro","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1177\/0883073809342005","article-title":"Pediatric low-grade gliomas","volume":"24","author":"Sievert","year":"2009","journal-title":"J Child Neurol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/2014.7.FOCUS14317","article-title":"Expanding indications for the extended endoscopic endonasal approach to hypothalamic gliomas: preliminary report","volume":"37","author":"Zoli","year":"2014","journal-title":"FOC"},{"key":"B35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/neuonc\/now209","article-title":"Pediatric low-grade gliomas: implications of the biologic era","volume":"19","author":"Packer","year":"2017","journal-title":"Neuro Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/neuonc\/nox141","article-title":"Pediatric low-grade gliomas: next biologically driven steps","volume":"20","author":"Jones","year":"2018","journal-title":"Neuro Oncol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1200\/JCO.2018.36.15_suppl.10537","article-title":"Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN)","volume":"36","author":"Geoerger","year":"2018","journal-title":"JCO"},{"key":"B39","doi-asserted-by":"publisher","first-page":"10504","DOI":"10.1002\/cam4.3910","article-title":"Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)\u2013associated plexiform neurofibroma: a phase I\/IIa study","volume":"36","author":"McCowage","year":"2018","journal-title":"JCO"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1002\/cam4.3910","article-title":"Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma","volume":"10","author":"Ronsley","year":"2021","journal-title":"Cancer Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11060-020-03592-8","article-title":"Trametinib for the treatment of recurrent\/progressive pediatric low-grade glioma","volume":"149","author":"Manoharan","year":"2020","journal-title":"J Neurooncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1212\/01.wnl.0000180409.78098.d7","article-title":"RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma","volume":"65","author":"Sharma","year":"2005","journal-title":"Neurology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation\u2013positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"i114","DOI":"10.1093\/neuonc\/noy059.387","article-title":"LGG-46. Trametinib therapy in pediatric patients with low-grade gliomas (lgg) with braf gene fusion; a disease-specific cohort in the first pediatric testing of trametinib","volume":"20","author":"Bouffet","year":"2018","journal-title":"Neuro Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3389\/fonc.2018.00526","article-title":"BRAF V600E inhibitor (vemurafenib) for BRAF V600E mutated low grade gliomas","volume":"8","author":"Del Bufalo","year":"2018","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1002\/ijc.33438","article-title":"Upfront treatment with mTOR inhibitor everolimus in pediatric low-grade gliomas: a single-center experience","volume":"148","author":"Cacchione","year":"2021","journal-title":"Int J Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00381-020-04724-1","article-title":"A systematic review of ongoing clinical trials in optic pathway gliomas","volume":"36","author":"Hill","year":"2020","journal-title":"Childs Nerv Syst"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.890875\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T02:39:50Z","timestamp":1655347190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.890875\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":49,"alternative-id":["10.3389\/fsurg.2022.890875"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.890875","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"article-number":"890875"}}